Gritstone Oncology, Inc. (GRTS): Price and Financial Metrics

Gritstone Oncology, Inc. (GRTS)

Today's Latest Price: $6.33 USD

0.36 (-5.38%)

Updated Jul 7 6:55pm

Add GRTS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

GRTS Stock Summary

  • With a one year PEG ratio of 0.27, Gritstone Oncology Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.07% of US stocks.
  • GRTS's went public 1.78 years ago, making it older than just 3.27% of listed US stocks we're tracking.
  • GRTS's price/sales ratio is 58.25; that's higher than the P/S ratio of 96.29% of US stocks.
  • Stocks that are quantitatively similar to GRTS, based on their financial statements, market capitalization, and price volatility, are AFMD, SPRO, MORF, UMRX, and CLDX.
  • Visit GRTS's SEC page to see the company's official filings. To visit the company's web site, go to
GRTS Daily Price Range
GRTS 52-Week Price Range

GRTS Stock Price Chart Technical Analysis Charts

GRTS Price/Volume Stats

Current price $6.33 52-week high $12.96
Prev. close $6.69 52-week low $5.42
Day low $6.29 Volume 725,500
Day high $6.76 Avg. volume 203,560
50-day MA $6.67 Dividend yield N/A
200-day MA $7.84 Market Cap 235.89M

Gritstone Oncology, Inc. (GRTS) Company Bio

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing personalized cancer immunotherapies for various cancer types in the United States. It is developing GRANITE-001, a personalized immunotherapy product for cancer patients; and SLATE-001 for patients with common tumor neoantigens. The company was founded in 2015 and is based in Emeryville, California.

GRTS Latest News Stream

Event/TimeNews Detail
Loading, please wait...

GRTS Latest Social Stream

Loading social stream, please wait...

View Full GRTS Social Stream

Latest GRTS News From Around the Web

Below are the latest news stories about Gritstone Oncology Inc that investors may wish to consider to help them evaluate GRTS as an investment opportunity.

Gritstone Oncology to Present Clinical Data from Ongoing GRANITE and SLATE Phase 1 Studies During Investor Webcast on July 13

EMERYVILLE, Calif., June 24, 2020 -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight.

Yahoo | June 24, 2020

Hedge Funds Are Done Selling Gritstone Oncology, Inc. (GRTS)

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 15, 2020

Gritstone Oncology (GRTS) Investor Presentation - Slideshow

The following slide deck was published by Gritstone Oncology, Inc. in conjunction with this event....

SA Transcripts | June 12, 2020

Gritstone Oncology Announces the Addition of Jean-Charles Soria, M.D., Ph.D., to its Scientific Advisory Board

Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Charles Soria, M.D., Ph.D., chief executive officer of Gustave Roussy Cancer Center, has joined the company’s scientific advisory board (SAB). “We are delighted that our co-founder Jean-Charles, a world-class medical oncologist and scientist, has rejoined our SAB following his tenure at AstraZeneca,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology.

Yahoo | June 10, 2020

Gritstone Oncology (GRTS): Strong Industry, Solid Earnings Estimate Revisions

Gritstone Oncology (GRTS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | May 22, 2020

Read More 'GRTS' Stories Here

GRTS Price Returns

1-mo -8.13%
3-mo -6.22%
6-mo -29.51%
1-year -44.67%
3-year N/A
5-year N/A
YTD -29.43%
2019 -41.94%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching GRTS

Here are a few links from around the web to help you further your research on Gritstone Oncology Inc's stock as an investment opportunity:

Gritstone Oncology Inc (GRTS) Stock Price | Nasdaq
Gritstone Oncology Inc (GRTS) Stock Quote, History and News - Yahoo Finance
Gritstone Oncology Inc (GRTS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9526 seconds.